

In re patent application of:

Ye, et al.

Appl. No.: 10/755,854

Filed: January 13, 2004

For: Eosinophil-Derived Neurotoxin as a

Marker for Ovarian Cancer

Art Unit: 1642

Examiner: J. Tidwell

Atty. Dkt.: 7570/80962

Second Supplemental Information Disclosure Statement

Commissioner of Patents
U.S. Patent and Trademark Office
Customer Service Window, MS Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Submitted herewith is a listing of documents known to Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. § 1.56. Copies of the listed documents, with the exception of United States patents, are also enclosed.

Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application. This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.

Consideration of the cited documents and making the same of record in the prosecution of the above-captioned application are respectfully requested.

Applicants do not believe any fees are due for the submission of this Information Disclosure Statement. However, the Director is hereby authorized to charge any fee deficiency to our Deposit Account No. 06-1135 under Order No. 7570/80962.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

Michael A. Sanzo Reg. No. 36,912

Attorney for Applicants

Date / une 8 , 200

1801 K Street, N.W., Suite 401L Washington, DC 20006-1201

1

Phone: (202) 419-7013

Atty. Docket No.: 7570/80962 Appl. No.: 10/755,854 LIST OF REFERENCES CITED BY APPLICAS (Use several sheets if necessary) Applicant(s) Ye, et al. JUN 0 8 5008 Filing Date: January 13, 2004 Group: 1642 . PATENT DOCUMENTS Examiner Document Filing Date Number Name Class Subclass If Appropriate Initial Date A 1 6,675,104 Jan. 6, 2004 Paulse, et al. 702 22 Nov. 15, 2001 2003/0087250 Monahan, (et al. A 2 May 8, 2003 435 6 Mar. 14, 2002 A 3 A 4 A 5 A 6 A 7 A 8 A 9 A 10 A 11 A 12 A 13 A 14 A 15 A 16 A 17 A 18 A 19 A 20 A 21 A 22 A 23 A 24 A 25 A 26 A 27 Examiner Date Considered

| | | • | Att. Doctor No. 7570/80062 | Annl No. 10/765 054 |
|---|------|---|---|---------------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | | | Atty. Docket No.: 7570/80962 | Appl. No.: 10/755,854 |
| | | | Applicant(s) Ye, et al. | |
| | | | Filing Date: January 13, 2004 | Group: 1642 |
| Examiner Initial | | OTHER PRIOR ART (Inclu | uding Author, Title, Date, Pertinent Pages, Etc.) | |
| | C 1 | BRAKORA, et al., "Utility of Osteopontin as a Biomarker in Recurrent Epithelial Ovarian Cancer," Gynoecologic Oncology 93:361-365 (2004). | | |
| | C 2 | FURGER, et al., "The Functional and Clinic 632 (2001). | | etastasis," Curr. Mol. Med. 1:621- |
| | C 3 | SCHORGE, et al., "Osteopontin as an Adjun 10:3474-3478 (2004). | nct to CA125 in Detecting Recurrent Ovar | rian Cancer," Clin. Cancer Res. |
| | C 4 | | | |
| | C 5 | | | |
| | C 6 | | | e e e e e e e e e e e e e e e e e e e |
| | C 7 | | | |
| \ | C 8 | | | |
| | C 9 | | | |
| - | C 10 | | | |
| | C 11 | | | |
| | C 12 | | | · |
| | C 13 | <u> </u> | | |
| | C 14 | | | |
| | C 15 | | | |
| | C 16 | | | |
| | C 17 | | | |
| | C 18 | | | <u> </u> |
| | C 19 | | | |
| | C 19 | | T | |
| Examiner | | | Date Considered | |